A Randomised, Double-blind, Placebo-controlled, Parallel Group Dose-finding Study of Linagliptin (1 and 5 mg Administered Orally Once Daily) Over 12 Weeks in Children and Adolescents, From 10 to 17 Years of Age, With Type 2 Diabetes Mellitus
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Linagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 16 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 10 Feb 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov record.
- 19 Sep 2015 Planned End Date changed from 1 Jan 2016 to 1 Feb 2016 as reported by ClinicalTrials.gov record.